ADARx Shares Rise in Nasdaq Debut
ADARx Pharmaceuticals shares gained thirty percent in their market debut Friday after raising $446.3 million in an upsized US initial public offering. The gene therapy developer sold 26.3 million shares at the top of its range.
Xurve View
Insights:
Xurve View
ADARx Pharmaceuticals rose 30% in its Nasdaq debut Friday after raising $446.3 million in an upsized United States initial public offering. The stock opened at $22.10, outperforming its $17 offer price. The offering follows a steady stream of biotech listings on United States exchanges as investors seek sectors insulated from geopolitical conflicts.
